StockMarketWire.com - IXICO has signed a new contract, with a top 15 global pharmaceutical company, utilising wrist worn activity sensors ('wearable biosensors') in a phase II clinical trial for a neurological disorder.

IXICO said this was its first commercial agreement using activity sensors to evaluate exploratory digital measures in early phase clinical research and followed a presentation of its approach to measuring sleep disturbances at the 'Mobile devices for clinical trials in neurological diseases workshop' earlier this year at the Clinical Data Interchange Standards Consortium and the Critical Path Institute Coalition Against Major Diseases meetings.

It said the contract had a value of around £0.5m over a two year term.

IXICO said it would utilise its biosensor clinical trial capabilities, combined with its artificial intelligence data analytics algorithms, to measure activity and sleep disturbances from biosensor data collected from c.300 people.






Story provided by StockMarketWire.com